CliniStart announced the company’s opening as a new services provider with specialty focus in clinical trial startup functions, specifically focused in the niche area of clinical trial contracting. The company manages all aspects of the clinical trial contract development and negotiations life cycle, as well as investigator grant budget processes with exceptional knowledge and skill.
Sam Searcy, CEO and key founder of CliniStart, previously cofounded Clintrax Global and served as a global contracting account leader for strategic partnerships with large pharma sponsors. “We believe that in the near future, CliniStart will be the preferred partner for clinical trial contract negotiations and investigator grant budget development for both pharmaceutical sponsors and industry CROs. Our services and software solutions will allow sponsors and CROs to focus on the crucial work of managing clinical trials.”
For more information, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.